McKesson reported $106.2 billion in fiscal Q3 2026 revenue, up 11% year-over-year, and raised full-year adjusted EPS guidance to $38.80-$39.20 — representing 17-19% earnings growth. Prescription volume from retail national accounts and oncology distribution drove the beat, with the U.S. Pharmaceutical segment generating the vast majority of revenue.

McKesson's results underscore the structural dominance of the drug distribution oligopoly. McKesson, AmerisourceBergen (now Cencora), and Cardinal Health collectively control approximately 90% of U.S. pharmaceutical distribution. In a healthcare economy where Medicaid contraction is squeezing providers and payers alike, the distributors are thriving on volume growth from specialty drugs, biosimilars, and GLP-1 medications. McKesson's oncology distribution business — anchored by its US Oncology Network of 2,400+ physicians — continues to benefit from the shift of cancer treatment to the community setting, where McKesson captures both distribution margin and practice management fees.

For healthcare organizations, McKesson's earnings signal that drug cost inflation remains a structural reality. The 11% revenue growth is driven by price increases and volume expansion in high-cost specialty categories, not efficiency gains. Dental practices with significant pharmaceutical spend — particularly oral surgery practices using specialty anesthetics, biologics, and regenerative materials — should expect continued upward pressure on supply costs. The PBM reform legislation may eventually shift formulary economics, but in the near term, distribution margins and specialty drug pricing continue to flow upward. McKesson's raised guidance also suggests confidence in sustained volume growth through at least mid-2026.

What to watch: McKesson's fiscal Q4 guidance commentary on GLP-1 distribution volumes and biosimilar uptake — both categories are reshaping the distribution revenue mix.